The U.S. Food and Drug Administration (FDA) has approved nixiFLOR injectable solution by Parnell Technologies, marking the first FDA-approved generic version of Resflor GOLD by Merck Animal Health. This product is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis, and for control of BRD-associated fever in beef and non-lactating dairy cattle.
nixiFLOR contains the same active ingredients as Resflor GOLD:
- Florfenicol, a broad spectrum antibiotic effective against key bacterial pathogens involved in BRD
- Flunixin meglumine, a non-steroidal anti-inflammatory drug (NSAID) that helps reduce fever and inflammation associated with respiratory infection
The FDA determined nixiFLOR is bioequivalent to the brand name product and that, when used according to the label, residues in edible tissues do not pose a public health concern. A withdrawal phase of 38 days must be observed before cattle treated with nixiFLOR enter the food supply.
Administered via subcutaneous injection in the neck, nixiFLOR is prescribed at 40 mg florfenicol/kg body weight and 2.2 mg flunixin/kg body weight (approximately 6 mL per 100lb. of body weight), with no more than 10 mL per injection site. This product is available by prescription only from licensed veterinarians, ensuring accurate diagnosis and responsible use.
